News

EMA changes biosimilar rules
Enlarge image

RegulatoryEUUKMalta

EMA changes biosimilar rules

01.10.2012 - The European Medicines Association has changed its biosimilars guidelines to make it easier to develop biologic follow-on drugs in both the US and Europe.

The London-based agency said it intends to accept batches of reference medicines sourced from outside the European Economic Area (EEA) in the future. This aims to facilitate the global development of biosimilars and avoid the unnecessary repetition of clinical trials.

Under the current European legal framework, companies developing a biosimilar medicine are required to identify a reference medicine that is or has been authorised in the European Economic Area (EEA) and whose batches are sourced from within the EEA. With the new approach, first announced by Commissioner John Dalli in Malta on 15 June 2012, the Agency will begin to accept reference medicine batches sourced from outside the EEA in certain pre-clinical and clinical studies in the comparability exercise.

A draft version of the new guidance is expectedearly next year. Since biosimilars became reality, EMA has become regardedas the most biosimilar-open agency in one of the biggest pharma markets.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/ema-accepts-foreign-biosimilar-data.html

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

IVFUKEU

04.02.2015 In a historic move, the UK is set to become the first country to allow the creation of babies with the genetic material of three people – a mother, a father and a female mitochondrial donor.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • MEDIGENE4.64 EUR7.16%
  • FORMYCON16.89 EUR4.07%
  • BIOFRONTERA1.99 EUR3.65%

FLOP

  • HBM102.00 CHF-2.86%
  • SYNGENTA327.00 CHF-2.15%
  • STRATEC BIOMEDICAL45.12 EUR-2.10%

TOP

  • WILEX3.17 EUR48.8%
  • EVOLVA1.70 CHF18.9%
  • MEDIGENE4.64 EUR16.6%

FLOP

  • MOLOGEN5.25 EUR-14.1%
  • SANTHERA98.45 CHF-10.3%
  • 4SC0.77 EUR-9.4%

TOP

  • SANTHERA98.45 CHF2457.1%
  • WILEX3.17 EUR403.2%
  • FORMYCON16.89 EUR115.7%

FLOP

  • CYTOS0.37 CHF-86.9%
  • MOLOGEN5.25 EUR-57.4%
  • PAION2.10 EUR-55.3%

No liability assumed, Date: 04.03.2015